PURA - Puration, Inc. Announces New Goldman Small Cap Research Report With Speculative-Buy Rating and Target $0.25 PPS
October 10 2018 - 9:20AM
InvestorsHub NewsWire
Dallas, TX -- October 10, 2018 -- InvestorsHub
NewsWire -- Puration, Inc. (USOTC:
PURA) today announced that Goldman Small Cap Research issued an
updated research report on the Company. The report includes a
'speculative-buy' rating with a target price-per-share
of $0.25. The report provides an in-depth overview and
analysis of Puration's successes, approach, new initiatives, and
upcoming milestones. To view the report, along with disclosures and
disclaimers, visit http://www.GoldmanResearch.com or https://www.purationinc.com/goldman-research/.
Puration Goldman Small Cap Research Report
Highlights
Puration, Inc. is a leading Texas-based,
CBD-infused beverage provider. The Company’s flagship product,
EVERx, which was introduced in 2017, targets the sports nutrition
market. Puration plans to introduce new beverages as well as grow
its product portfolio organically as well as through targeted
acquisitions. As of October 2018, the Company was set to spin off
its cannabis cultivation segment to focus its efforts exclusively
on its high-growth core CBD-infused beverage
business.
According to Hemp Business Journal, the overall
hemp-based CBD market is forecast to grow from $820 million in 2017
to $1.9 billion in 2022 and given that the market remains
fragmented, fast-growing PURA is well positioned to capture market
share very quickly.
In the
Opportunity Research update, analyst Rob Goldman discusses the
Company’s compelling positioning, exciting opportunities, and
innovative subsidiary spin-off plans.
Goldman
noted, “PURA is one of the leading players in the fast-growing
CBD-infused beverage arena. In fact, Puration’s flagship product
has enjoyed 600% sales growth since its introduction in 2017.
Leveraging this growth, Puration plans to execute M&A and
introduce new beverage products. With double the number of CBDs
found in most beverages, PURA’s EVERx CBD Infused Sports Waters
reduce pain and muscle soreness.”
“Major
beverage companies such as Constellation Brands, Coca-Cola have
already begun joint venture with companies in the cannabis space or
are devising their strategies. These recent events bode well for
companies like Puration which has demonstrated sales and a strong
customer base sports nutrition and fitness. To focus on its core, high-growth beverage business,
PURA announced a spin-off of its cannabis cultivation segment,
effective 10/11/18. This event could turn into a future bonus for
shareholders.”
“In our view, these
shares are trading at very low levels and offer substantial upside.
A snapshot of the current valuations of 2 publicly traded cannabis
beverage peers illustrates that PURA trades at a lower market cap,
despite much higher sales. Thus, we believe the stock could reach
higher levels as PURA executes its sales and M&A
strategy.”
About Goldman Small Cap
Research: Founded in
2009 by former Piper Jaffray analyst and mutual fund manager Rob
Goldman, Goldman Small Cap Research produces sponsored and
non-sponsored small cap and microcap stock research reports,
articles, stock market blogs, and popular investment
newsletters.
Goldman
Small Cap Research is not in any way affiliated with Goldman Sachs
& Co.
This
press release contains excerpts of our most recently published
sponsored company research report on Puration, Inc. which carries a
rating and a price target. The information used and
statements of fact made have been obtained from sources considered
reliable but we neither guarantee nor represent the completeness or
accuracy. Goldman Small Cap Research
relied solely upon information derived from Puration, Inc. (“the
Company”) authorized press releases or legal disclosures made in
its filings with the U.S. Securities and Exchange Commission
http://www.sec.gov.
Separate from the
factual content of our report about the Company, we may from time
to time include our own opinions about the Company, its business,
markets and opportunities. Any opinions we may offer about the
Company are solely our own, and are made in reliance upon our
rights under the First Amendment to the U.S. Constitution, and are
provided solely for the general opinionated discussion of our
readers. Our opinions should not be considered to be complete,
precise, accurate, or current investment advice. Statements herein
may contain forward-looking statements and are subject to
significant risks and uncertainties affecting
results.
A
Goldman Small Cap Research report, update, newsletter, article,
trading alert, corporate profile, or press release is not intended
as an offering, recommendation, or a solicitation of an offer to
buy or sell the securities mentioned or discussed is to be used for informational purposes
only. Please read all associated full disclosures,
disclaimers, and analyst background on our website before
investing. Neither Goldman Small Cap Research nor its parent is a
registered investment adviser or broker-dealer with FINRA or any
other regulatory agency. To download this research report or any of
our research, view our disclosures and disclaimers, or for more
information, visit www.goldmanresearch.com. Goldman Small Cap
Research was compensated $3500 by the Company for research and
distribution services, including the production of this press
release.
About Puration, Inc. (OTC -
PURA) Puration, Inc.
is a leading Texas-based, CBD-infused beverage provider. The
Company’s flagship product, EVERx, which was introduced in 2017,
targets the sports nutrition market. Puration plans to introduce
new beverages as well as grow it product portfolio organically as
well as through targeted acquisitions. As of October 2018, the
Company was set to spin off its cannabis cultivation segment to
focus its efforts exclusively on its high-growth core CBD-infused
beverage business.
For
more information, please visit: www.PurationInc.com
Disclaimer/Safe
Harbor:
This news release
contains forward-looking statements within the meaning of the
Securities Litigation Reform Act. The statements reflect the
Company's current views with respect to future events that involve
risks and uncertainties. Among others, these risks include the
expectation that any of the companies mentioned herein will achieve
significant sales, the failure to meet schedule or performance
requirements of the companies' contracts, the companies' liquidity
position, the companies' ability to obtain new contracts, the
emergence of competitors with greater financial resources and the
impact of competitive pricing. In the light of these uncertainties,
the forward-looking events referred to in this release might not
occur. These statements have not been evaluated by the Food and
Drug Administration. These products are not intended to diagnose,
treat, cure, or prevent any disease.
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800) 861-1350
Goldman Small Cap Research
Rob Goldman, Analyst
410-609-7100
rob@goldmanresearch.com
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Sep 2023 to Sep 2024